Real-time US stock event calendar and catalyst tracking for understanding upcoming market-moving announcements. Our event calendar helps you prepare for earnings releases, product launches, and other important dates.
On April 21, 2026, Merck (MRK) announced that U.S. FDA granted priority review to two supplemental biologics license applications (sBLAs) for its Keytruda (both intravenous and subcutaneous formulations) in combination with Pfizer’s antibody-drug conjugate (ADC) Padcev, for the treatment of cisplati
Pfizer Inc. (PFE) – Padcev Combination Therapy Receives FDA Priority Review for Expanded Bladder Cancer Indication - Expert Verified Trades
PFE - Stock Analysis
3711 Comments
1755 Likes
1
Enley
Engaged Reader
2 hours ago
I reacted emotionally before understanding.
👍 87
Reply
2
Hilia
Active Reader
5 hours ago
This feels like I just unlocked level confusion.
👍 297
Reply
3
Casimer
Trusted Reader
1 day ago
Market breadth is moderate, reflecting mixed participation across different stock categories.
👍 129
Reply
4
Beny
Experienced Member
1 day ago
Great overview, especially the discussion on momentum and volume dynamics.
👍 288
Reply
5
Tekia
Insight Reader
2 days ago
The market is reacting to macroeconomic developments, creating temporary volatility.
👍 192
Reply
© 2026 Market Analysis. All data is for informational purposes only.